Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would you please just go find another stock to bad mouth? You're starting to get annoying. If I knew where you lived I would walk up to your door and punch you in the mouth.
Why has there been like 0 volume over the last few days?
Its also past 90 days from when they announced the 90 day bridging trial of Lodonal with HIV/AIDS patients. Having seen results from that but that news maybe coming out soon as well. That was announced on 5/4/2015
Climbing fast and big again today. Lots of big things going on. Are they about to go public?
Does anyone think this will ever get back above $1?
Wow. This has just been a waste of time and money with this crap. Noreen is scam artist. Great job.
I unfortunately was sucked into this one a while ago and have been stuck riding this dead horse into the ground. Might as well stick around for the comedy of errors. Be almost impossible to make up the money lost on this bloodsucker.
This is turning into a complete joke. Noreen is a crook and thats all there is to it. If she denies that, then just plain flat out sucks at her job. Just waiting to watch this hit 0.
Wow is all I have to say. Looks like we are supporting their grandchildrens college education. This is a joke. How do they get away with this?
Its always interesting to me when the bid is higher than the ask. Just doesnt quite make sense to me.
Only 12 trading days away. We're getting closer. I am ready to see where this goes. I'm betting on over $1.50 in 30 days. Tons of potential here.
Cruise control now. Wish I loaded even more last week. Sitting on a huge chunk though and looking forward to what the future may hold.
Exactly. There is a ton of promise here. Everyone was just trying to beat it down to pick up cheap shares. I just picked more and more up the whole way down. Now its time to reap the benefits. The bid looks heavy and the ask is thin. Going to move up quickly. Especially once this is spun off(8/15) into Cytocom. CEO is a proven leader and winner. They have investors lined up and some drugs in the pipeline. No brainer to me.
Very Important news below from the statement:
Cytocom, Inc., has received interest from two investment banking firms to underwrite and fund Cytocom pursuant to a S-1 Registration Statement that would fund the company's development plan.
"Upon the spin-off, Cytocom will be able to focus on its development stage, targeted immunology and oncology pipeline and once spin-off and distribution is complete, Cytocom will operate as a stand-alone publicly traded company," said Dr. Graham Burton President and CEO of Cytocom
Spin off is pushed out another 30 days. At that time all shares will be converted 1-1 into Cytocom. There seems to be quite an interest in the developed of Cytocom. Should make for an interesting ride. I've held onto these shares for quite some time now and am ready to start recovering some losses here and get into the green.
Looks like we maybe going back up. Tomorrow is the supposed spinoff date. Doubt thats happening.
Pink sheets man. Could jump right back to a dollar next week. Whatever the manipulators want to do with it until real news comes out. Once it uplists it's go time.
This is some bs. What the hell is going on here?
Same with me but this is starting to get boring. I've waited this long so I might as well stick it out through July.
I've heard the same from some pretty good places. Uplisting in the works.
I'm lost. They announce the spin off and the approval of one of there drugs within days of each other and the stock goes down. Both of these are significant milestones and yet it goes down.
What gives?
How is this not blowing up?
This is awesome news. Once this gets out amongst everyone, watch out. Looking forward to what is to come.
We have to be getting close to go time. Still waiting for the ride north.
What the heck just happened?
Got some confidence in this now. No one selling below the ask. Bids are chasing it up. Time for uplisting soon?
Starting to make some moves in the right direction. Is this the start of something more? Get ready for a ride soon.
This is an exciting time for TNIB. People are starting to realize the potential here and when it starts to move, watch out. This is going to surprise a lot of people in less than 30 days. Get ready.
Thought you were buying at .50. Ha at least we don't have to listen to your bashing crap anymore
Really? 0 shares sold so far. Is it halted or what?
No he cant prove anything. He can only flap his gums.
They are making it tough to hold onto this. I know what the possibilities are here but it's almost hard to see it right now.
Good night that was a massive dip. Hopefully it does the opposite today. Starts down and creeps up into the green.
Hmmm....Can anyone guess whats going to happen today? Up early and then drop all day into the red.
Seems like the same thing everyday. Up early and then step down all day long.
Are we going to continue stepping this down or are we going to finish strong?
A lot of good news coming out as of late. This will soar any day now. I'm hanging tight and will be here for a while to milk this one.
TNI BioTech, Inc. Granted Additional Patent for Methods for Inducing Sustained Immune Response of T-Cells
ORLANDO, Fla., March 12, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells.
The present invention relates to methods of stimulating and promoting a sustained natural immune system response, resulting in increased resistance and inhibition of infectious agents, including viruses, bacteria, fungi and parasites, and other immunodeficiency-related ailments. More specifically, the invention relates to an intermittent dose schedule for promoting a sustained increased level of T-cell production (cytotoxic T-cells) including CD3, CD4, CD8, natural killer (NK) cells, CD38 cells, and interleukin II receptor. Pursuant to the patent, these therapies can be used on immunocompromised individuals including patients with cancer, or undergoing x-ray, surgery, or chemotherapy treatments.
The patent assigned to TNI BioTech from Nicholas Plotnikoff, which is already the subject of a previously granted U.S. patent, protects the activated NK cells. Similar patent protection has been obtained in India, Russia and the United Kingdom.
IRT-101 (MENK) is an active immunotherapy with MENK for patients with deficient functioning of the immune system. It works by restoring the patient's immune functions and by activating the lymphocytes to attack cancer cells and infectious diseases, such as HIV/AIDS. This is accomplished because MENK binds to opioid receptors on both immune cells and on cancer cells, which directly inhibits the growth of cancer cells and increases the number and functions of T-cells, NK cells, NK-T cells, and gamma/delta T-cells. These cells then destroy infective organisms and tumor cells while simultaneously inhibiting the ability of T regulatory (Treg) cells to block the functions of anti-cancer or anti-infectious disease lymphocytes.
Noreen Griffin, CEO of TNI BioTech said, "We are pleased to be able to expand our patent portfolio and believe this patent plus the many other patents surrounding MENK provide us with broad composition-of-matter protection for our suite of immunotherapy treatments."
About TNI BioTech, Inc.
TNI BioTech, Inc. is a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin ("MENK") (sometimes referred to as opioid growth factor ("OGF")) and our Low Dose Naltrexone product ("LDN"), which have been shown to stimulate the immune system even in patients with advanced cancer. Even though management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of the following: autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as an adjunct to antibiotics in the treatment of a variety of infectious diseases, including patients with AIDS, in combination with retroviral drug therapy.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release and the statements of representatives and partners of TNI Biotech, Inc. and its subsidiaries (the "Company") related thereto include various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" used in the Company's press releases and in the Company's filings with the Securities and Exchange Commission as well as Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve assumptions and significant risks and uncertainties. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release, and thus readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
For further information, please see:
http://www.tnibiotech.com
Contact:
Dennis S. Dobson
203-258-0159
dennisdobsonjr@dobsonmediagroup.com
SOURCE TNI BioTech, Inc.
/Web site: http://www.tnibiotech.com
Since you said so. You seem like a real credible person. I'll go ahead and take your advice. Haha.
Uplisting.